Skip to content

The impact of moxibustion on digestive system function and gut bacteria pattern in chronic kidney disease patients undergoing peritoneal dialysis

Study on clinical effect and mechanism of moxibustion therapy in improving gastrointestinal dysfunction in uremia peritoneal dialysis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN14267067
Enrollment
102
Registered
2024-04-10
Start date
2020-03-01
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease peritoneal dialysis patients Urological and Genital Diseases

Interventions

From March 2020 to February 2022, 52 patients with chronic kidney failure (CRF) who received moxibustion combined with peritoneal dialysis (PD) in our hospital (moxibustion group) and 50 patients with

Sponsors

Shanghai Sixth People's Hospital Jinshan Branch
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged > 18 years old; 2. Clinical diagnosis of CRF with specific indications for PD.

Exclusion criteria

Exclusion criteria: 1. Decreased peritoneal clearance rate caused by various abdominal lesions; 2. Within 3 days of abdominal surgery and no complete healing of the wound, which could easily lead to dialysate leaks; 3. Localized inflammatory lesions in the peritoneum, which could be spread by PD; 4. Late pregnancy or large intra-abdominal tumors, which could result in reduced abdominal volume and subsequent unsatisfactory effect of PD; 5. Extensive abdominal wall infection or severe burns, which could cause failure of intubation; 6. Intra-abdominal vascular diseases, such as polyangiitis, severe arteriosclerosis, scleroderma, which could reduce the dialysis efficacy; 7. Severe respiratory insufficiency; in such patients, excessive fluid intake would aggravate respiratory insufficiency, and if the patients were still required to receive PD, fluid intake was less; 8. Long-term insufficiency of protein and caloric intake; such patients were not suitable for PD because PD could lead to daily loss of protein more than 6 g

Design outcomes

Primary

MeasureTime frame
1. After 12 weeks of treatment, gastrointestinal function was analyzed by blood tests of secretion of gastrin, motilin, cholecystokinin, somatostatin and growth hormone releasing peptide before and after treatment. 2. Fecal samples were collected 12 weeks after treatment for 16S rDNA analysis to observe changes in fecal microbial characteristics

Secondary

MeasureTime frame
Renal function index: After 12 weeks of treatment, Blood routine markers and blood electrolytes were detected by blood. Routine biochemical parameters and 24-hour urinary protein quantification (UPQ) by urine testing

Countries

China

Contacts

Public ContactKun Liu
saynever2004@126.com+86 136 1179 5408

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026